1st Circ. Won't Revive Nexium Pay-For-Delay Suit
The First Circuit kept a 2014 jury verdict for AstraZeneca PLC and Ranbaxy Inc. intact, finding Monday that a class of direct and indirect buyers of heartburn medication Nexium who alleged...To view the full article, register now.
Already a subscriber? Click here to view full article